Ph.D. in Medical Science | Research Director

Dr Ragnarson Tennvall earned her PhD in Medicine, Health Economics, at Lund University in 2001 on the thesis “The Diabetic foot – Costs, health economic aspects, prevention and quality of life”. She has 20 years of experience in the development and application of economic evaluations in health care. Her research includes empirical economic analyses and evaluations of pharmaceuticals and other medical technologies. Recent and on-going research includes analyses of registry data on haemophilia and endometriosis. Health economic analyses of interventions in different dermatological diseases are other on-going research. She is interested in quality of life measurement and QALYs.

Dr Ragnarson Tennvall participated as health economist in the preparation of the National Guidelines for care of prostate cancer and breast cancer at the National Board of Health and Welfare (Socialstyrelsen) in 2005-2007.

Dr Ragnarson Tennvall is a member of the EURODIALE Consortium, a European study group for diabetes and complications of the lower extremities.

Disease Areas
       • Dermatology
       • Diabetes
       • Haematological disease
       • Oncology
       • Parkinson´s disease

Boulton A J M, Vileikyte L, Ragnarson Tennvall G & Apelqvist J. The global burden of diabetic foot disease. Lancet 2005; 366(12):1719-24.

Hjelmgren J, Persson U & Ragnarsson Tennvall G. Local treatment pattern versus trial-based data: A cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden. American Journal of Therapeutics 2005; 12(5): 425-430.

Ragnarson Tennvall G. Economic factors. In Bakker K, Foster A, van Houtum W, Riley P (Eds). Put feet first prevent amputations. Diabetes and foot care. IDF, International Diabetes Federation, Brussels, 2005.

Ragnarson Tennvall G & Hjelmgren J. Annual costs of treatment for venous leg ulcers in Sweden and the United Kingdom.
Wound Repair and Regeneration 2005;13 (1):13-18.

Ragnarson Tennvall G & Apelqvist J. Health economic consequences of diabetic foot lesions. Clinical Infectious Diseases 2004;39: S132-9.

Fyhr, A., Jendteg, S., Ragnarson Tennvall, G., Cavallin-Ståhl, E. & Wain, R. Costs of preparing cytotoxic drugs by nurses on hospital wards or by pharmcists in preparation centres. Journal of Social and Administrative Pharmacy 2001:18(5);193-197.

Ragnarson Tennvall G. The diabetic foot – Costs, health economic aspects, prevention, and quality of life. Thesis, Lund University, 2000.

Ragnarson Tennvall G & Apelqvist J. Prevention of diabetes-related foot ulcers and amputations – A cost-utility analysis based on Markov model simulations. Diabetologica 2001:44;2007-2087.

Ragnarson Tennvall G, Apelqvist J. Health-related quality of life in patients with diabetes mellitus and foot ulcers. Journal of Diabetes and Its Complications 2000: 14; 235-241.

Ragnarson Tennvall G, Apelqvist J, Eneroth M. Costs of deep foot infections in patients with diabetes mellitus. Pharmacoeconomics, 2000: 18(3); 225-238

Ragnarson Tennvall G, Apelqvist J, Eneroth M. The inpatient care of patients with diabetes mellitus and foot ulcers. A validation study of the correspondence between medical records and the Swedish Inpatient Registry with the consequences for cost estimations. Journal of Internal Medicine 2000: 248; 397-405.